Knowledge Insight: PIIINP as a Non-Invasive Biomarker for Renal Fibrosis
09 Apr 2026
Knowledge Insight: PIIINP as a Non-Invasive Biomarker for Renal Fibrosis
Concept
Renal fibrosis is the pathological hallmark of progressive chronic kidney disease (CKD), featured by excessive accumulation of extracellular matrix proteins—predominantly type I and type III collagen. Procollagen Type III N-terminal Propeptide (PIIINP) is a stable byproduct released during type III collagen biosynthesis; its concentration in urine and serum directly reflects the activity of fibrogenesis.
Research Frontier
Current clinical evaluation of renal fibrosis relies on invasive renal biopsy, which carries risks of sampling error and cannot support real-time monitoring. The latest research focuses on non-invasive urinary PIIINP detection as a dynamic biomarker for assessing fibrosis severity, predicting CKD progression, and evaluating therapeutic efficacy. High-specificity antibodies enable standardized, quantitative, and multi-center comparable detection.
Research Significance
PIIINP testing addresses critical unmet needs in nephrology:
- Enables non-invasive, repeatable assessment of renal fibrosis
- Reduces unnecessary renal biopsies and clinical risks
- Supports dynamic monitoring of anti-fibrotic treatment response
- Predicts CKD progression and renal function decline
- Facilitates standardized diagnosis across laboratories
Core Mechanisms and Detection Methodology
Biological Basis of PIIINP
- Type III collagen is scarce in healthy renal tissue but strongly upregulated in fibrosis
- PIIINP is a 42 kDa trimeric peptide with a short circulating half-life
- Levels correlate with collagen synthesis rate and interstitial fibrosis severity
Key Clinical Findings
- Urinary PIIINP/creatinine ratio is significantly higher in CKD patients than healthy controls
- The ratio strongly correlates with histological fibrosis scores (BANFF and image analysis)
- A ratio >800 ng/mmol yields 94% negative predictive value for non-diagnostic renal biopsy
- eGFR and disease type are independent influencing factors
Detection Technology
High-performance immunoassays (ELISA, RIA) based on recombinant rabbit monoclonal anti-PIIINP antibodies provide:
- High sensitivity and specificity
- Excellent intra‑ and inter‑assay reproducibility
- Reliable sample stability during storage
- Support for point-of-care testing development
Product Empowerment
ANT BIO PTE. LTD. offers the PIIINP Recombinant Rabbit Monoclonal Antibody (SDT‑149‑50, Cat. No. S0B3138) under its Starter product line. This high‑quality reagent enables accurate and consistent detection of PIIINP in biological samples, supporting renal fibrosis research, clinical diagnostics, and multi‑center studies.
Core Product Advantages
| Core Product Advantages |
|---|
| High Specificity: Precisely recognizes human PIIINP with minimal cross‑reactivity; strong signal and low background in serum, urine, and cell supernatants. |
| Excellent Stability & Batch Consistency: Strict quality control ensures minimal inter‑batch variation and long‑term stability, supporting reliable clinical and research applications. |
| Broad Compatibility: Fully validated for ELISA, Western Blot (WB), and other immunoassays; adaptable to clinical diagnostics and translational research. |
Key Application Scenarios
| Key Application Scenarios |
|---|
| Renal Fibrosis Assessment: Non‑invasive staging, dynamic monitoring, and prognostic evaluation in CKD. |
| Systemic Fibrosis Diseases: Auxiliary diagnosis of liver, pulmonary, and myocardial fibrosis. |
| Tissue Remodeling Research: Evaluation of collagen synthesis during wound repair and post‑injury recovery. |
| Cardiovascular Risk Evaluation: Assessment of vascular and myocardial fibrosis in hypertension and atherosclerosis. |
| Connective Tissue Disorders: Monitoring disease activity in systemic sclerosis and related conditions. |
Brand Mission
ANT BIO PTE. LTD. is a leading provider of life science reagents, offering antibodies, recombinant proteins, assay kits, and general laboratory reagents. We operate three specialized sub‑brands: Absin (general reagents & kits), Starter (antibodies), and UA (recombinant proteins), delivering integrated solutions for nephrology, fibrosis research, biomarker development, and precision diagnostics. We are committed to advancing non‑invasive detection and personalized care for chronic kidney disease.
Related Product List
| Product Name | Catalog No. | Applications |
|---|---|---|
| PIIINP Recombinant Rabbit Monoclonal Antibody (SDT‑149‑50) | S0B3138 | ELISA, WB, sample detection |
| PIIINP ELISA Assay Kit | Absin series | Quantitative urinary/serum testing |
| Renal Fibrosis Biomarker Panel | Starter series | Multi‑marker combined detection |
| Protein Stabilization Buffers | Absin series | Sample preservation and stability |
Brand Promotion Copy
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights
